

ASX ANNOUNCEMENT

APPOINTMENT OF ROBERT IERVASI AS INDEPENDENT CHAIR OF THE BOARD

13 FEBRUARY 2024

Melbourne, Australia – Vitura Health Limited (ASX: VIT) (**Vitura and Company**) is pleased to announce that, following an extensive recruitment search, Mr. Robert Iervasi has been appointed as Independent Chair and a Non-Executive Director of the Board, replacing Dr. Marcia Walker who has held the position of Interim Chair since September 2023. Dr. Walker will remain on the Board as an independent, Non-Executive Director.

The Board would like to thank Dr. Walker for her valuable contribution to the Company and her service as Interim Chair and looks forward to her continued leadership as an independent, Non-Executive Director.

Mr. Iervasi is a Chair, Board Director, former Group CEO, CFO and General Counsel. Most recently he was the Group CEO of Asahi Beverages, which owns Carlton and United Breweries (CUB). In this role, he was instrumental in the acquisition of CUB by Asahi in 2019 in a deal valued at \$16 billion.

Currently, Mr. Iervasi serves as Chair at Luv-a-Duck and Charters Paper, and is a Non-Executive Director at SPC Global.

With a background in both corporate governance and consumer products, Mr. Iervasi is focussed on driving profitability and growth, utilising decades of experience as a CFO, General Counsel and CEO through the various executive and Board roles he has held, including Asahi Beverages, HS Fresh Foods Group, Allpress Espresso and Circular Plastics Australia. In these roles, he has leveraged a proven ability to identify opportunities, mitigate enterprise-wide risks and implement revenue and cost synergies.

Mr. Iervasi pays special attention to employee engagement which he believes is integral to the success of an integrated business and is, now more than ever, core business for boards. He has achieved this in previous roles whilst delivering above-market top-line and profit growth.

Reflecting on his significant commercial experience and proven FMCG experience, Mr. Iervasi is well placed to lead the Board of Vitura to enhance its operational performance, guide future acquisitions and integrations and to optimise its operating model to generate sustainable financial growth.

Mr. Iervasi holds a Bachelor of Commerce (Honours) majoring in Accounting and Finance, and a Bachelor of Laws (Honours) degree and has completed the Senior Executive Program at London Business School.



“Robert brings a wealth of experience to Vitura having recently concluded a distinguished executive career at a global level with Asahi Beverages as Group CEO, which delivered exceptional operational, and financial growth and the \$16 billion acquisition of CUB. The Vitura team looks forward to building on our foundational growth under Robert’s Chairmanship,” said Rodney Cocks, Chief Executive Officer of Vitura.

“Joining Vitura at this time represents an exciting opportunity. The growth already achieved by Vitura, coupled with Vitura’s relentless ambition to enhance the healthcare experience, means that we are well placed to continue to grow and excite our consumers. I am looking forward to bringing my experience in consumer products and FMCG to Vitura as we work towards redefining healthcare in our markets,” said Mr. Iervasi.

Mr. Iervasi’s remuneration as Chair of Vitura is \$120,000 per annum and he will join the Company’s Audit and Risk and Nomination and Remuneration Committees.

** ENDS **



About Vitura Health Limited (ASX:VIT)

www.vitura.com.au

Vitura Health Limited is diversified digital health business listed on the ASX (ASX:VIT) and, via its wholly owned subsidiaries, operates the following businesses:

- www.burleighheadscannabis.com
Burleigh Heads Cannabis operates the market leading prescriber, patient, pharmacy and supplier online ecosystem, CanView, which sells and distributes 350+ therapeutic product and device SKUs within Australia from approximately 40 international and domestic brands.
- www.canview.com.au
CanView is being developed to be a complete end-to-end healthcare ecosystem designed to provide doctors, pharmacists and patients with a simple and cost-effective way to facilitate the treatment of patients with increased efficiency and compliance. The CanView system is based on a medicines wholesaling platform which seamlessly brings together a number of disparate SAAS (software-as-a-service) providers including inventory control, invoicing, customer management, reporting and analytics, all linked together through customised integration from third party providers. Underpinning the suite of SAAS elements are a number of bespoke, internally-generated operating procedures and intellectual property assets, supported by the CanView customer support and infield customer engagement teams. Through the integration of the different elements which together make up CanView, the platform provides the best user experience in the industry.

Through the Company's relationships with third party integrators, CanView provides Australian doctors with the ability to integrate their patient management systems directly with the platform and to use their patient information to generate electronic prescriptions within the CanView platform, without the need to input the patient's details. Prescriptions are then sent directly to the CanView patient app where patients can manage their treatment and submit the prescription and subsequent repeats to one of the 4,100+ Australian pharmacies with accounts on CanView for dispensing.

While the Company's current operations focus on the sale and distribution of medicinal cannabis products, Vitura is fully licensed and equipped, via its two state-of-the-art distribution centres in Melbourne and the Gold Coast, to distribute all products under Schedules 2, 3, 4, 8 and 9. The establishment during the year of the Company's joint venture to distribute psychedelic products, including MDMA and Psilocybin, is a timely example of the many opportunities that the Company believes can be seamlessly integrated into its existing digital health platform business.

- www.doctorsondemand.com.au
The Company owns Doctors on Demand Pty Ltd, a nationwide 24/7 x 365 telehealth platform business that provide innovative primary health solutions to hundreds of thousands of B2C and B2B patients annually. Services include general medical consults, urgent care, medical certificates, pathology referrals, specialist referrals, men's health, women's health, medicated weight loss and smoking cessation.
- www.cortexa.com.au
The Company owns 50% of Cortexa Pty Ltd, an incorporated joint venture with Canadian-based PharmAla Biotech (CSE:MDMA). Cortexa aims to be the leading supplier of psychedelics, GMP MDMA and GMP psilocybin, for research and therapeutic use in Australia.
- www.cdaclinics.com.au
The Company owns CDA Clinics that undertakes nationwide telehealth consultations with patients seeking access to medicinal cannabis.



- www.cannadoc.com.au

The Company owns 75.5% of Cannadoc Health Pty Ltd, a medicinal cannabis clinic business that undertakes nationwide telehealth consultations with patients seeking access to medicinal cannabis.

Authorised by

Rodney Cocks, Chief Executive Officer and Executive Director

Contact

Vitura Health Limited

Rodney Cocks

Chief Executive Officer and Executive Director

1300 799 491

info@vitura.com.au

Media enquiries

Tim Fogarty

The Civic Partnership

+61 400 179 075

tim.fogarty@civicpartners.com.au

Forward-looking statements

This announcement includes forward-looking statements which may be identified by words such as 'anticipates', 'believes', 'expects', 'intends', 'may', 'will', 'could', or 'should' and other similar words that involve risks and uncertainties. These forward-looking statements are based on the Company's expectations and beliefs concerning future events as at the date of this announcement. Forward-looking statements are necessarily subject to risks, uncertainties and other factors, many of which are outside the control of the Company, which could cause actual results to differ materially from such statements. The Company makes no undertaking to update or revise the forward-looking statements made in this announcement to reflect any change in circumstances or events after the date of this announcement.